pyridoxine has been researched along with Chemotherapy-Induced Acral Erythema in 11 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Colorectal cancer patients scheduled to receive capecitabine chemotherapy as adjuvant therapy were randomly assigned to receive TJ-28 (7500 mg/day) or oral pyridoxine (60 mg/day)." | 9.34 | The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102). ( Endo, I; Fujii, S; Ichikawa, Y; Ishibe, A; Oba, MS; Ota, M; Watanabe, J; Watanabe, K, 2020) |
| "Pyridoxine, an activated form of vitamin B6 used to treat allergic dermatitis, may prevent capecitabine-associated hand-foot syndrome (HFS), although evidence of the benefit of prophylactic pyridoxine is lacking." | 9.27 | A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. ( Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A, 2018) |
| "Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment." | 9.24 | Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. ( Chay, WY; Chia, JWK; Choo, SP; Dent, RA; Koh, KX; Koo, WH; Kwok, LL; Lo, SK; Loh, M; Mok, ZY; Ng, RCH; Soong, RCT; Syn, N; Tan, S; Tham, CK; Toh, HC; Wong, NS; Yap, YS, 2017) |
| "Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice." | 9.22 | Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. ( Hung, CH; Kao, YS; Lo, CH; Tu, YK, 2022) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 9.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| " Colorectal cancer patients scheduled to receive capecitabine chemotherapy as adjuvant therapy were randomly assigned to receive TJ-28 (7500 mg/day) or oral pyridoxine (60 mg/day)." | 5.34 | The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102). ( Endo, I; Fujii, S; Ichikawa, Y; Ishibe, A; Oba, MS; Ota, M; Watanabe, J; Watanabe, K, 2020) |
| "Pyridoxine, an activated form of vitamin B6 used to treat allergic dermatitis, may prevent capecitabine-associated hand-foot syndrome (HFS), although evidence of the benefit of prophylactic pyridoxine is lacking." | 5.27 | A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. ( Hattori, M; Hayashi, T; Iwata, H; Kobayashi, N; Nakada, T; Saito, K; Sawaki, M; Toyama, T; Tsuneizumi, M; Yokota, I; Yoshimura, A, 2018) |
| "Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment." | 5.24 | Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial. ( Chay, WY; Chia, JWK; Choo, SP; Dent, RA; Koh, KX; Koo, WH; Kwok, LL; Lo, SK; Loh, M; Mok, ZY; Ng, RCH; Soong, RCT; Syn, N; Tan, S; Tham, CK; Toh, HC; Wong, NS; Yap, YS, 2017) |
| "Capecitabine-induced hand-foot syndrome (HFS) is common in clinical practice." | 5.22 | Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials. ( Hung, CH; Kao, YS; Lo, CH; Tu, YK, 2022) |
| "BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine." | 5.19 | The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014) |
| "A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily." | 5.16 | A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. ( Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G, 2012) |
| "Celecoxib was effective in preventing HFS in patients who received capecitabine (50." | 2.82 | Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. ( Franco, PIG; Li, RK; Pandy, JGP, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Pandy, JGP | 1 |
| Franco, PIG | 1 |
| Li, RK | 1 |
| Kao, YS | 1 |
| Lo, CH | 1 |
| Tu, YK | 1 |
| Hung, CH | 1 |
| Watanabe, K | 2 |
| Ishibe, A | 1 |
| Watanabe, J | 2 |
| Ota, M | 2 |
| Fujii, S | 1 |
| Ichikawa, Y | 2 |
| Oba, MS | 1 |
| Endo, I | 2 |
| Lian, S | 1 |
| Zhang, X | 1 |
| Zhang, Y | 1 |
| Zhao, Q | 1 |
| Charalambous, A | 1 |
| Tsitsi, T | 1 |
| Astras, G | 1 |
| Paikousis, L | 1 |
| Filippou, E | 1 |
| Yap, YS | 1 |
| Kwok, LL | 1 |
| Syn, N | 1 |
| Chay, WY | 1 |
| Chia, JWK | 1 |
| Tham, CK | 1 |
| Wong, NS | 1 |
| Lo, SK | 1 |
| Dent, RA | 1 |
| Tan, S | 1 |
| Mok, ZY | 1 |
| Koh, KX | 1 |
| Toh, HC | 1 |
| Koo, WH | 1 |
| Loh, M | 1 |
| Ng, RCH | 1 |
| Choo, SP | 1 |
| Soong, RCT | 1 |
| Toyama, T | 1 |
| Yoshimura, A | 1 |
| Hayashi, T | 1 |
| Kobayashi, N | 1 |
| Saito, K | 1 |
| Tsuneizumi, M | 1 |
| Sawaki, M | 1 |
| Hattori, M | 1 |
| Nakada, T | 1 |
| Yokota, I | 1 |
| Iwata, H | 1 |
| Ozkol, HU | 1 |
| Calka, O | 1 |
| Bulut, G | 1 |
| Jo, SJ | 1 |
| Shin, H | 1 |
| Jo, S | 1 |
| Kwon, O | 1 |
| Myung, SK | 1 |
| Tatsumi, K | 1 |
| Suwa, H | 1 |
| Osada, S | 1 |
| Tanaka, K | 1 |
| Shoichi, F | 1 |
| Kunisaki, C | 1 |
| Corrie, PG | 1 |
| Bulusu, R | 1 |
| Wilson, CB | 1 |
| Armstrong, G | 1 |
| Bond, S | 1 |
| Hardy, R | 1 |
| Lao-Sirieix, S | 1 |
| Parashar, D | 1 |
| Ahmad, A | 1 |
| Daniel, F | 1 |
| Hill, M | 1 |
| Wilson, G | 1 |
| Blesing, C | 1 |
| Moody, AM | 1 |
| McAdam, K | 1 |
| Osborne, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Placebo Control Randomised Trial to Test the Effectiveness of Vitamin B6 in Hand Foot Syndrome[NCT02625415] | 54 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Randomized Double-Blind Placebo-Controlled Trial of Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome (HFS)[NCT00486213] | Phase 3 | 210 participants (Actual) | Interventional | 2007-06-30 | Terminated (stopped due to Slow accrual) | ||
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246] | Phase 2 | 66 participants (Anticipated) | Interventional | 2022-12-08 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pyridoxine and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Topics: Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Neoplasms; Pyridoxine; Randomized Controlled Tr | 2022 |
Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Hand-Foot Syndrome; Humans; Network Meta-A | 2022 |
Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Topics: Antineoplastic Agents; Capecitabine; Hand-Foot Syndrome; Humans; Pyridoxine | 2021 |
Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Topics: Antineoplastic Agents; Dietary Supplements; Disease Management; Hand-Foot Syndrome; Humans; Prospect | 2015 |
6 trials available for pyridoxine and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102).
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug The | 2020 |
A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD).
Topics: Activities of Daily Living; Administration, Topical; Adult; Aged; Antibiotics, Antineoplastic; Antim | 2021 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Squ | 2017 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Squ | 2017 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Squ | 2017 |
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Asian People; Capecitabine; Chi-Squ | 2017 |
A randomized phase II study evaluating pyridoxine for the prevention of hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Topics: Aged; Breast Neoplasms; Capecitabine; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Meta | 2018 |
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan | 2014 |
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diseas | 2012 |
1 other study available for pyridoxine and Chemotherapy-Induced Acral Erythema
| Article | Year |
|---|---|
Chemotherapy-induced acral erythema with involvement of the face and neck: A case report.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Dr | 2016 |